ArticleJournal of gastrointestinal cancer2026
Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLorazepam is frequently used in pancreatic cancer patients receiving chemotherapy for its antiemetic properties and to mitigate psychological distress. However, N-unsubstituted benzodiazepines like lorazepam may adversely impact pancreatic cancer progression by stimulating fibrosis and inflammatory signaling. This study aimed to retrospectively compare the survival rates of pancreatic cancer patients exposed to lorazepam with those who were not exposed to real-world clinical practice.
methodsData were retrospectively reviewed from patients aged ≥ 18 years with pathologically confirmed pancreatic cancer who received palliative chemotherapy at Seoul National University Hospital between January 2011 and January 2023. Patients were dichotomized based on lorazepam administration: those who received ≥ 15 mg (equivalent to ≥ 1 tablet daily for 30 days) were classified as the high-dose group, and those who received < 15 mg were classified as the low-dose group. The relationship between lorazepam exposure and progression-free survival (PFS), as well as overall survival (OS), was analyzed.
resultsAmong pancreatic cancer patients undergoing palliative chemotherapy, PFS was worse in the high-dose lorazepam group compared to the low-dose group [median, 6 months (5–7) vs. 8 months (7–9), p = 0.025]. However, there was no difference in OS between the two groups [median, 11 months (10–12) vs. 12 months (11–13), p = 0.465].
conclusionHigher cumulative lorazepam exposure was associated with shorter progression-free survival in Asian patients with pancreatic cancer treated with palliative chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.